Initial performance evaluation of a spotted array Mobile Analysis Platform (MAP) for the detection of influenza A/B, RSV, and MERS coronavirus

Justin Hardick, David Metzgar, Lisa Risen, Christopher Myers, Melinda Balansay, Trent Malcom, Richard Rothman, Charlotte Gaydos

Research output: Contribution to journalArticlepeer-review

Abstract

Clinical samples were evaluated with the Mobile Analysis Platform (MAP) to determine platform performance for detecting respiratory viruses in samples previously characterized using clinical reverse transcriptase polymerase chain reaction assays. The percent agreement between MAP and clinical results was 97% for influenza A (73/75), 100% (21/21) for influenza B, 100% (6/6) for respiratory syncytial virus (RSV), and 80% (4/5) for negative specimens. The approximate limit of detection of the MAP was 30 copies/assay for RSV and 1500 copies/assay for Middle East respiratory syndrome coronavirus.

Original languageEnglish (US)
Pages (from-to)245-247
Number of pages3
JournalDiagnostic Microbiology and Infectious Disease
Volume91
Issue number3
DOIs
StatePublished - Jul 2018

Keywords

  • MERS
  • Point-of-care diagnostics
  • Respiratory viruses

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Initial performance evaluation of a spotted array Mobile Analysis Platform (MAP) for the detection of influenza A/B, RSV, and MERS coronavirus'. Together they form a unique fingerprint.

Cite this